Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3)
Phase 2
- Conditions
- resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000003402
- Lead Sponsor
- Miyagi HBPCOG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1) pulmonary fibrosis or interstitial pneumonitis 2) tumor other than ductal carcinoma 3) distant metastasis 4) R2 resection 5) prior anti-cnacer therapy 6) pregnancy 7) under 18 years old
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method